537 related articles for article (PubMed ID: 21193545)
61. [Correlation between interleukin-1 and the obesity of polycystic ovary syndrome].
Yang Y; Qiao J; Li MZ
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):9-13. PubMed ID: 22455686
[TBL] [Abstract][Full Text] [Related]
62. High serum concentration of total inhibin in polycystic ovary syndrome.
Tsigkou A; Luisi S; De Leo V; Patton L; Gambineri A; Reis FM; Pasquali R; Petraglia F
Fertil Steril; 2008 Nov; 90(5):1859-63. PubMed ID: 18423626
[TBL] [Abstract][Full Text] [Related]
63. Can environmental pollutant bisphenol A increase metabolic risk in polycystic ovary syndrome?
Milanović M; Milošević N; Sudji J; Stojanoski S; Atanacković Krstonošić M; Bjelica A; Milić N; Medić Stojanoska M
Clin Chim Acta; 2020 Aug; 507():257-263. PubMed ID: 32387634
[TBL] [Abstract][Full Text] [Related]
64. Reproductive hormone levels and anthropometry in postmenopausal women with polycystic ovary syndrome (PCOS): a 21-year follow-up study of women diagnosed with PCOS around 50 years ago and their age-matched controls.
Schmidt J; Brännström M; Landin-Wilhelmsen K; Dahlgren E
J Clin Endocrinol Metab; 2011 Jul; 96(7):2178-85. PubMed ID: 21508129
[TBL] [Abstract][Full Text] [Related]
65. Androgen Profile Through Life in Women With Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study.
Pinola P; Piltonen TT; Puurunen J; Vanky E; Sundström-Poromaa I; Stener-Victorin E; Ruokonen A; Puukka K; Tapanainen JS; Morin-Papunen LC
J Clin Endocrinol Metab; 2015 Sep; 100(9):3400-7. PubMed ID: 26192874
[TBL] [Abstract][Full Text] [Related]
66. Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients.
Karadağ C; Yoldemir T; Gogas Yavuz D
Gynecol Endocrinol; 2017 Mar; 33(3):234-237. PubMed ID: 27908213
[TBL] [Abstract][Full Text] [Related]
67. Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-α levels in non-obese women with polycystic ovary syndrome.
Choi YS; Yang HI; Cho S; Jung JA; Jeon YE; Kim HY; Seo SK; Lee BS
Steroids; 2012 Nov; 77(13):1352-8. PubMed ID: 22944040
[TBL] [Abstract][Full Text] [Related]
68. Endocrine Disruptors and Polycystic Ovary Syndrome: Phthalates.
Akın L; Kendirci M; Narin F; Kurtoğlu S; Hatipoğlu N; Elmalı F
J Clin Res Pediatr Endocrinol; 2020 Nov; 12(4):393-400. PubMed ID: 32431137
[TBL] [Abstract][Full Text] [Related]
69. Endocrine disruptors, obesity, and cytokines - how relevant are they to PCOS?
Šimková M; Vítků J; Kolátorová L; Vrbíková J; Vosátková M; Včelák J; Dušková M
Physiol Res; 2020 Sep; 69(Suppl 2):S279-S293. PubMed ID: 33094626
[TBL] [Abstract][Full Text] [Related]
70. Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome.
Chen MJ; Chiu HM; Chen CL; Yang WS; Yang YS; Ho HN
J Clin Endocrinol Metab; 2010 Jul; 95(7):3332-41. PubMed ID: 20427499
[TBL] [Abstract][Full Text] [Related]
71. Is muscle mechanical function altered in polycystic ovary syndrome?
Caliskan Guzelce E; Eyupoglu D; Torgutalp S; Aktoz F; Portakal O; Demirel H; Yildiz BO
Arch Gynecol Obstet; 2019 Sep; 300(3):771-776. PubMed ID: 31263987
[TBL] [Abstract][Full Text] [Related]
72. In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls.
Economou F; Xyrafis X; Livadas S; Androulakis II; Argyrakopoulou G; Christakou CD; Kandaraki E; Palioura E; Diamanti-Kandarakis E
Hormones (Athens); 2009; 8(3):199-206. PubMed ID: 19671519
[TBL] [Abstract][Full Text] [Related]
73. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome.
Demi R İ; Guler A; Alarslan P; Isil AM; Ucman O; Aslanipour B; Calan M
Endocrine; 2019 Jul; 65(1):175-183. PubMed ID: 31154608
[TBL] [Abstract][Full Text] [Related]
74. Effects of androgen excess and body mass index on endothelial function in women with polycystic ovary syndrome.
Berbrier DE; Leone CA; Adler TE; Bender JR; Taylor HS; Stachenfeld NS; Usselman CW
J Appl Physiol (1985); 2023 Apr; 134(4):868-878. PubMed ID: 36861670
[TBL] [Abstract][Full Text] [Related]
75. Serum bisphenol A analogues in women diagnosed with the polycystic ovary syndrome - is there an association?
Jurewicz J; Majewska J; Berg A; Owczarek K; Zajdel R; Kaleta D; Wasik A; Rachoń D
Environ Pollut; 2021 Mar; 272():115962. PubMed ID: 33223334
[TBL] [Abstract][Full Text] [Related]
76. Effects of vitamin D supplementation on insulin sensitivity and androgen levels in vitamin-D-deficient polycystic ovary syndrome patients.
Karadağ C; Yoldemir T; Yavuz DG
J Obstet Gynaecol Res; 2018 Feb; 44(2):270-277. PubMed ID: 29094433
[TBL] [Abstract][Full Text] [Related]
77. Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome.
Fulghesu AM; Manca R; Loi S; Fruzzetti F
Fertil Steril; 2015 Mar; 103(3):808-14. PubMed ID: 25637475
[TBL] [Abstract][Full Text] [Related]
78. The Association Between Bisphenol A and Polycystic Ovarian Syndrome: A Case-Control Study.
Hossein Rashidi B; Amanlou M; Behrouzi Lak T; Ghazizadeh M; Haghollahi F; Bagheri M; Eslami B
Acta Med Iran; 2017 Dec; 55(12):759-764. PubMed ID: 29373882
[TBL] [Abstract][Full Text] [Related]
79. Bisphenol-A and polycystic ovary syndrome: a review of the literature.
Kechagias KS; Semertzidou A; Athanasiou A; Paraskevaidi M; Kyrgiou M
Rev Environ Health; 2020 Nov; 35(4):323-331. PubMed ID: 32663175
[TBL] [Abstract][Full Text] [Related]
80. Serum irisin and its regulation by hyperinsulinemia in women with polycystic ovary syndrome.
Adamska A; Karczewska-Kupczewska M; Lebkowska A; Milewski R; Górska M; Otziomek E; Nikolajuk A; Wolczynski S; Kowalska I
Endocr J; 2016 Dec; 63(12):1107-1112. PubMed ID: 27616010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
